China SXT Pharmaceuticals, Inc. (SXTC) Comparison with companies in other sectors?

China SXT Pharmaceuticals, Inc. has a share price of 116.03M. You can analyze China SXT Pharmaceuticals, Inc. (SXTC) competitors across different market sectors through stock heatmaps.

What are SXTC's NET and operating margins?

China SXT Pharmaceuticals, Inc. (SXTC) operating margin is around 6.91, and net profit margin is approximately 6.67 as of the latest reports.

In what way does SXTC's earnings per share (EPS) trend reflect its financial momentum?

China SXT Pharmaceuticals, Inc. (SXTC) EPS is 124.50 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for China SXT Pharmaceuticals, Inc. is 0.01, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for China SXT Pharmaceuticals, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for China SXT Pharmaceuticals, Inc. like P/E which is 0.30, P/B which is 0.14, and PEG which is 0.008. Compare them with sector averages to evaluate if the stock is priced fairly.

China SXT Pharmaceuticals, Inc.

SXTC•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$1.59

$-0.03(-1.85%)

Fundamental Analysis of China SXT Pharmaceuticals, Inc. (SXTC)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$124.50

P/E Ratio

0.01

ROE

0.47%

Net Margin

6.67%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$184.48M

Shares OutstandingTotal number of shares issued

$116.03M

Book Value/ShareNet worth per share

$11.29

Revenue/ShareAnnual revenue per share

$0.80

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$124.5

Net MarginNet income as percentage of revenue

667.16%

Operating MarginOperating income as percentage of revenue

691.04%

ROEReturn on shareholders' equity

47.36%

ROAReturn on total assets

28.53%

ROCEReturn on capital employed

48.04%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-1.10

Cash/ShareCash and equivalents per share

$9.79

FCF YieldFree cash flow as percentage of market cap

-0.73%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SXTCFinancial Ratios Analysis details for SXTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SXTCSector Benchmarking details for SXTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for China SXT Pharmaceuticals, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of China SXT Pharmaceuticals, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account China SXT Pharmaceuticals, Inc.'s unique business strengths and challenges.

Key Financial Metrics for China SXT Pharmaceuticals, Inc.

For China SXT Pharmaceuticals, Inc., essential financial indicators include EPS 124.50, PE 0.01, and ROE 0.47. These key ratios reveal insights into China SXT Pharmaceuticals, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare China SXT Pharmaceuticals, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of China SXT Pharmaceuticals, Inc.

Metrics like Net Margin 667.16% and ROA 28.53% shed light on how well China SXT Pharmaceuticals, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether China SXT Pharmaceuticals, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of China SXT Pharmaceuticals, Inc.

Using ratios such as P/B Ratio 0.14 and PEG Ratio 0.008, investors can assess whether China SXT Pharmaceuticals, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with China SXT Pharmaceuticals, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for China SXT Pharmaceuticals, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.19 and Cash Flow $-1.10, provide a snapshot of China SXT Pharmaceuticals, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like China SXT Pharmaceuticals, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for China SXT Pharmaceuticals, Inc.

Investing in China SXT Pharmaceuticals, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at China SXT Pharmaceuticals, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;